In ovarian cancer, FGF18 was identified as a blood‐based biomarker by secretome analysis and enhanced FGF18 levels were confirmed by ELISA in the blood from ovarian cancer patients compared with a control group.24 The gene discussed is FGF18; the disease is ovarian carcinoma.